Thelansis

  Pancreatic Cancer (PC) is a lethal malignancy, with its prevalence, although relatively low, steadily increasing each year. Metastatic PC, categorized as late-stage (stage IV), represents the most advanced form of the disease, boasting an even higher fatality rate compared to other stages. Notably, patients affected by PC typically lack specific clinical manifestations. The major signaling pathways in metastatic pancreatic cancer include Epithelial-Mesenchymal Transition (EMT) and NF-κB (nuclear factor-κ-light-chain-enhancer activated B cells). Upon diagnosis, it is frequently observed that PC has already metastasized to a significant extent, rendering curative surgery unfeasible. However, imaging techniques such as CT, utilizing X-rays to generate cross-sectional images of the body, play a pivotal role in accurately assessing metastatic spread and offering crucial insights into treatment strategies, especially for tumors on the borderline of resectability. With the advanced st...